Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy – A multicentre study of 90 patients from the German Dermatooncology Group
Imke Grimmelmann(Medizinische Hochschule Hannover), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Rudolf Herbst(Helios Klinikum Erfurt), Claudia Pföhler(Saarland University), Corinna Kochanek(Medizinische Hochschule Hannover), Katharina C. Kähler(Christian-Albrechts-Universität zu Kiel), Friedegund Meier(National Center for Tumor Diseases), Lucie Heinzerling(LMU Klinikum), M Momma(Diabetes Australia), Thomas Eigentler(University Children's Hospital Tübingen), Carola Berking(Universitätsklinikum Erlangen), Selma Ugurel(Klinikum Bielefeld), Lisa Zimmer(The University of Sydney), Jessica C. Hassel(German Cancer Research Center), Carmen Loquai(Johannes Gutenberg University Mainz), Cristel Ruini(LMU Klinikum), Jochen Utikal(German Cancer Research Center), Kai‐Martin Thoms(Universitätsmedizin Göttingen), Dirk Debus(Nuremberg Hospital)
Cited by 26
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k